J. Rosenberg

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

DG Maloney, TM Liles, DK Czerwinski et al. · Blood · 1994 · 747 citations

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 2000 · 688 citations

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

DG Maloney, A.J. Grillo-López, David Bodkin et al. · Journal of Clinical Oncology · 1997 · 636 citations

Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) [RETIRED]

Robert G. Miller, J. Rosenberg, Deborah Gelinas et al. · Neurology · 1999 · 574 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Neurological Disorder +7

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein, A.J. Grillo-López, Christine A. White et al. · Annals of Oncology · 1998 · 520 citations · Full text

Anti-tumor Response, Lymphoid Neoplasia, Hematological Malignancy +10